Copenhagen, 2016-07-13 13:07 CEST (GLOBE NEWSWIRE) -- As previously disclosed in company announcement of 11 July 2016, QIAGEN N.V. has initiated a compulsory redemption of the minority shareholders in Exiqon A/S in accordance with sections 70 and 72 of the Danish Companies Act. Based on this, the board of directors of Exiqon A/S decided to request Nasdaq Copenhagen A/S for a delisting and cancellation from trading of all shares in Exiqon A/S, whereby the last day of trading would be 3 August 2016. Nasdaq Copenhagen A/S has today accepted such a request.
Consequently, the last day of trading for the Exiqon shares will be 3 August 2016.
Additional information
Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)
About Exiqon
At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon’s research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visit www.exiqon.com